SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8178)1/4/1999 10:34:00 PM
From: LarryS  Read Replies (2) | Respond to of 17367
 
Michael Murphy will be on Squawk Box
tomorrow. Hopefully he will push
biotech as one of the best ways to
invest your money in '99. Hopefully
one of those investments he pushes
will be XOMA, after all he just bought
back in. With some luck he might even
bring us new information on trials, deals,
etc.



To: aknahow who wrote (8178)1/4/1999 11:20:00 PM
From: Robert K.  Respond to of 17367
 
from cnbc>8:00am Squawk Box
Vincent Farrell
Spears, Benzak, Salomon & Farrell

Gregory Jones
uBid Chairman & CEO

Ian Livingston
Eidos Chairman

Michael Murphy
California Technology Stock Letter Editor



To: aknahow who wrote (8178)1/5/1999 12:18:00 AM
From: Tharos  Respond to of 17367
 
George, as always I appreciate seeing this information because it reaffirms my belief that there is a reasonably substantial overseas market for Neuprex to treat meningitis, but I must admit I am a skeptic as to any statistical relevance this data may have. Not all facilities in England are conducting Neuprex trials. It would be very difficult to extrapolate deaths/treated patients/test centers from the data, all necessary to form an educated analysis of Neuprex's affects.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News